Nursing Elites

1. Which of the following are manifestations of Cushing syndrome?

• A. Truncal obesity with thin extremities.
• B. Enlargement of face, hands, and feet.
• C. Cachexia.
• D. Thick scalp hair.

Correct answer: A

Rationale: Truncal obesity with thin extremities is a classic manifestation of Cushing syndrome due to the redistribution of fat. Enlargement of face, hands, and feet is seen in conditions like acromegaly, not Cushing syndrome. Cachexia is a state of severe weight loss and muscle wasting, typically seen in conditions like cancer or advanced infections. Thick scalp hair is not typically associated with Cushing syndrome.

2. A patient is administered a nucleotide reverse transcriptase inhibitor in combination with a nonnucleotide reverse transcriptase inhibitor. What is the main rationale for administering these medications together?

• A. They improve treatment adherence.
• B. They reduce the duration of illness.
• C. They exhibit synergistic antiviral effects.
• D. They prevent opportunistic infections.

Correct answer: C

Rationale: The main rationale for administering a nucleotide reverse transcriptase inhibitor in combination with a nonnucleotide reverse transcriptase inhibitor is that they exhibit synergistic antiviral effects when used together. This combination enhances their antiviral activity against HIV by targeting different steps in the viral replication cycle. Choice A is incorrect because the rationale for combining these medications is based on their antiviral effects, not treatment adherence. Choice B is incorrect because the primary purpose of combination therapy is not to reduce the duration of illness but to improve treatment efficacy. Choice D is incorrect as the main focus of this combination is not on preventing opportunistic infections but on directly targeting the HIV virus.

3. A patient is taking medroxyprogesterone acetate (Provera) for the treatment of endometriosis. What should the nurse teach the patient about this medication?

• A. Medroxyprogesterone should be taken with food to prevent nausea.
• B. Medroxyprogesterone should be taken at the same time each day to maintain consistent hormone levels.
• C. Medroxyprogesterone can be taken intermittently when symptoms worsen.
• D. Medroxyprogesterone should be stopped if side effects occur.

Correct answer: B

Rationale: The correct answer is B. Medroxyprogesterone should be taken at the same time each day to maintain consistent hormone levels and effectiveness. Choice A is incorrect because medroxyprogesterone does not necessarily need to be taken with food. Choice C is incorrect as it is typically prescribed continuously rather than intermittently. Choice D is incorrect because patients should not stop the medication if side effects occur without consulting their healthcare provider.

4. What is the primary role of albumin in the blood?

• A. Transport oxygen throughout the body.
• B. Serve as a key clotting factor.
• C. Maintain osmotic pressure and fluid balance.
• D. Act as an immune response molecule.

Correct answer: C

Rationale: The correct answer is C: Maintain osmotic pressure and fluid balance. Albumin plays a crucial role in maintaining osmotic pressure by helping to retain fluid within the blood vessels. This function is essential for regulating blood volume and preventing fluid from leaking out into tissues. Choices A, B, and D are incorrect because albumin is not primarily responsible for transporting oxygen, acting as a clotting factor, or functioning as an immune response molecule in the blood.

5. A patient is diagnosed with ischemic heart disease. She is prescribed filgrastim (Neupogen). What effect will this medication provide in the treatment of ischemic heart disease?

• A. Increase platelets
• B. Decrease platelets
• C. Promote angiogenesis
• D. Prevent thrombus formation

Correct answer: C

Rationale: Filgrastim (Neupogen) is a medication that promotes the growth of white blood cells. In the context of ischemic heart disease, promoting angiogenesis, the formation of new blood vessels, can improve blood flow to the heart muscle, reducing ischemia and potentially improving cardiac function. Therefore, the correct answer is C. Choices A and B are incorrect because filgrastim does not directly affect platelet levels. Choice D is also incorrect as filgrastim does not prevent thrombus formation.

Similar Questions